Product Description
Bradanicline, a novel small molecule that modulates the activity of the neuronal nicotinic receptor (NNR) subtype known as alpha7(alpha7). Bradanicline belongs to a new class of drugs for the treatment of central nervous system diseases and disorders. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Bradanicline)
Mechanisms of Action: nAChR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Catalyst Biosciences
Company Location: CORAL GABLES FL 33134
Company CEO: Patrick J. McEnany
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Cognitive Dysfunction|Attention Deficit Disorder with Hyperactivity|Schizophrenia|Chronic Cough
Phase 1: Alzheimer Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ATA101-PN-001 | P2 |
Completed |
Chronic Cough |
2019-05-07 |
23% |
| 2011-005138-21 | P2 |
Completed |
Schizophrenia |
2013-11-08 |
|
| TC-5619-23-CRD-003 | P2 |
Completed |
Cognitive Dysfunction|Schizophrenia |
2013-11-01 |
|
| TC-5619-238-CRD-004 | P2 |
Completed |
Attention Deficit Disorder with Hyperactivity |
2012-07-01 |